GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tsubota Laboratory Inc (TSE:4890) » Definitions » ROCE %

Tsubota Laboratory (TSE:4890) ROCE % : -147.46% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tsubota Laboratory ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tsubota Laboratory's annualized ROCE % for the quarter that ended in Dec. 2023 was -147.46%.


Tsubota Laboratory ROCE % Historical Data

The historical data trend for Tsubota Laboratory's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsubota Laboratory ROCE % Chart

Tsubota Laboratory Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
ROCE %
1.15 43.04 23.13 9.64 -36.07

Tsubota Laboratory Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.67 -34.22 -49.41 -147.46 96.49

Tsubota Laboratory ROCE % Calculation

Tsubota Laboratory's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=-635.366/( ( (2672.961 - 607.728) + (2295.159 - 837.547) )/ 2 )
=-635.366/( (2065.233+1457.612)/ 2 )
=-635.366/1761.4225
=-36.07 %

Tsubota Laboratory's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-2187.188/( ( (2311.483 - 496.671) + (2002.197 - 850.582) )/ 2 )
=-2187.188/( ( 1814.812 + 1151.615 )/ 2 )
=-2187.188/1483.2135
=-147.46 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tsubota Laboratory  (TSE:4890) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Tsubota Laboratory ROCE % Related Terms

Thank you for viewing the detailed overview of Tsubota Laboratory's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tsubota Laboratory (TSE:4890) Business Description

Traded in Other Exchanges
N/A
Address
34 Shinanomachi, 304 Toshin Shinanomachi-ekimae Building, Shinjuku-ku, Tokyo, JPN, 160-0016
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.

Tsubota Laboratory (TSE:4890) Headlines

No Headlines